Eudra GMP - Public Layout

MIA | GMP | API REG | WDA | GDP | Sites

Help

Fri 6 Nov 2026 21:07:59 BST

GMP Compliance Menu

GMP Certificates

Non-Compliance Report

The Certificate has been withdrawn, withdrawn date is : 2026-07-16

Print Preview

Print Preview (Short version)

Back To Search

Austrian Federal Office For Safety In Health Care

CERTIFICATE NUMBER: 482159-104397091

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1) , (2)

Part 1

Issued following an inspection in accordance with
Art. 94(1) of Regulation (EU) 2019/6 as amended
Art. 111(5) of Directive 2001/83/EC as amended
Art. 63 of Regulation (EU) 536/2014 as amended

The competent authority of Austria confirms the following:

The manufacturer: Fresenius Kabi Austria GmbH

Site address:

Am Gewerbepark 6, Werndorf, 8402

OMS Organisation Id. / OMS Location Id.: ORG-100000614 / LOC-100001745

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. 482159 in accordance with Art. 88 of Regulation (EU) 2019/6, Art. 61 of Regulation (EU) No 536/2014 and Art. 40 of Directive 2001/83/EC, transposed in the following national legislation:§ 63 Medicines Act (Arzneimittelgesetz) and Ordinance 2009 (Arzneimittelbetriebsordnung 2009).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2024-11-07 , it is considered that it complies with:

The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572 and/or Commission Delegated Regulation (EU) 2017/1569, as reflected by the product categories stated in Part 2. (3)

The principles and guidelines of Good Manufacturing Practice laid down in Directive 91/412/EEC. (3)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or clarifying remarks can be identified through the EudraGMDP website (https://eudragmdp.ema.europa.eu/). This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

__________________________________________________________________________________________________________________________

(1) The certificate referred to in paragraph Art. 80(5) of Directive 2001/82/EC, Art. 111(5) of Directive 2001/83/EC and Art. 15 of Directive 2001/20/ECis also applicable to importers.
(2) Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate.
(3) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products
Human Investigational Medicinal Products
Veterinary Medicinal Products

1 MANUFACTURING OPERATIONS

1.4 Other products or manufacturing activity

1.4.3 Other: Lagerung von Ausgangsmaterialien und Primärpackmitteln sowie visuelle Kontrolle / Storage of raw materials and primary packaging materials as well as visual inspection, Lagerung von Ausgangsmaterialien und Primärpackmitteln sowie visuelle Kontrolle / Storage of raw materials and primary packaging materials as well as visual inspection(en)

1.5 Packaging

1.5.2 Secondary packaging

1.6 Quality control testing

1.6.3 Chemical/Physical

2 IMPORTATION OF MEDICINAL PRODUCTS

2.3 Other importation activities

2.3.1 Site of physical importation
2.3.4 Other: Import biotechnologischer Produkte, eingeschränkt auf Biosimilars / Import of biotechnological products restricted to Biosimilars, Import biotechnologischer Produkte, eingeschränkt auf Biosimilars / Import of biotechnological products restricted to Biosimilars(en)

Clarifying remarks (for public users):

Hersteller klinischer Prüfpräparate: Fresenius Kabi Austria GmbH; ad 1.6.3: Eingeschränkt auf Tätigkeiten der Endkontrolle: Packmittel Funktionsprüfungen sowie Probenahme von Ausgangsmaterialien und Primärpackmitteln inklusive hochaktiven Substanzen / Limited to operations of final inspections of primary packaging and sampling of starting materials and primary packaging materials including highly active substances Probebetrieb betreffend Verfahren 1035…; Hersteller Arzneimittel: Fresenius Kabi Austria GmbH; ad 1.6.3: Eingeschränkt auf Tätigkeiten der Endkontrolle: Packmittel Funktionsprüfungen sowie Probenahme von Ausgangsmaterialien und Primärpackmitteln inklusive hochaktiven Substanzen / Limited to operations of final inspections of primary packaging and sampling of starting materials and primary packaging materials including highly active substances Probebetrieb betreffend Verfahren 1035…;

Withdrawal comments in English: Superseded because new certificate was issued following an inspection

Withdrawal comments in National Language: Superseded because new certificate was issued following an inspection

The EudraGMDP database is maintained and operated by the EMA. Access to the general public is granted in order to enhance availability of information related to the EMA mandate. The content of the database is provided by the National Competent Authorities (NCA) of the EEA. For this reason, the EMA accepts no responsibility or liability whatsoever (including but not limited to any direct or consequential loss or damage it might occur to you and/or any other third party) arising out of or in connection with the information on this database. Any questions about the content should be addressed to the relevant NCA. Please click here to get list of NCA's.

For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI.

Documents issued by UK authorities up to and including 31 December 2020 remain available for consultation in EudraGMDP. However, they are no longer included or updated from 1 January 2021, with the exception of the documents pertaining to sites located in Northern Ireland.